MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

Condition(s) studied

Investigational drug(s) / intervention(s)

Prediction of molecular pathology: Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI

Study summary

This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.

Eligibility

Primary outcome measure(s)

• AUC of prediction performance — up to 10 years
  AUC=sensitivity+specificity-1

Trial sites (1)

More The First Affiliated Hospital of Zhengzhou University trials in China

Other trials for the same condition